Dr. Cerchietti is physician scientist dedicated to translational research in hematology oncology. His lab conduct mechanistic studies on the genetic, metabolic, and epigenetic regulation of lymphoma and microenvironment cells. Therapeutic approaches developed from his lab have been successfully translated to patients in investigator-initiated to cooperative group phase 3 clinical trials. Dr. Cerchietti also developed biomarkers to improve the precision of these interventions. Successfully translated research includes the concept of epigenetic priming to improve chemotherapy and immunotherapy as well as the discovering of the mechanism of action of XPO1 inhibitors in lymphomas contributing to gain FDA approval. A major focus of his lab is the study of the microenvironment to provide novel therapeutic targets as well as patient selection biomarkers (the “LME” classification) to improve the precision of therapies and increase disease curability.